Compagnie Lombard Odier S Cm A Avadel Pharmaceuticals PLC Transaction History

Compagnie Lombard Odier S Cm A

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	SELL	$6.41 - $9.95 $256,400 - $398,000	-40,000 Reduced 76.92%	12,000 $109,000
Q4 2022 Feb 13, 2023	BUY	$5.02 - $10.0 $165,660 - $330,000	33,000 Added 173.68%	52,000 $372,000
Q1 2022 Apr 27, 2022	BUY	$5.46 - $8.29 $70,980 - $107,769	13,000 Added 216.67%	19,000 $130,000
Q2 2020 Aug 14, 2020	SELL	$7.25 - $11.75 $94,250 - $152,750	-13,000 Reduced 68.42%	6,000 $48,000
Q3 2017 Nov 14, 2017	BUY	$8.35 - $10.5 $158,650 - $199,500	19,000	19,000 $199,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Compagnie Lombard Odier S Cm A, based on Form 13F filings with the SEC.

Stay updated on Compagnie Lombard Odier S Cm A with notifications on news.